MRNS
Price
$0.54
Change
-$0.00 (-0.00%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
29.76M
55 days until earnings call
QLGN
Price
$4.05
Change
-$0.05 (-1.22%)
Updated
Jan 14 closing price
Capitalization
2.98M
Ad is loading...

MRNS vs QLGN

Header iconMRNS vs QLGN Comparison
Open Charts MRNS vs QLGNBanner chart's image
Marinus Pharmaceuticals
Price$0.54
Change-$0.00 (-0.00%)
Volume$23.1K
Capitalization29.76M
Qualigen Therapeutics
Price$4.05
Change-$0.05 (-1.22%)
Volume$7.92K
Capitalization2.98M
MRNS vs QLGN Comparison Chart
Loading...
MRNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRNS vs. QLGN commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNS is a Buy and QLGN is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (MRNS: $0.54 vs. QLGN: $4.05)
Brand notoriety: MRNS and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRNS: 87% vs. QLGN: 16%
Market capitalization -- MRNS: $29.76M vs. QLGN: $2.98M
MRNS [@Biotechnology] is valued at $29.76M. QLGN’s [@Biotechnology] market capitalization is $2.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNS’s FA Score shows that 0 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • MRNS’s FA Score: 0 green, 5 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than MRNS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNS’s TA Score shows that 4 TA indicator(s) are bullish while QLGN’s TA Score has 2 bullish TA indicator(s).

  • MRNS’s TA Score: 4 bullish, 5 bearish.
  • QLGN’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, MRNS is a better buy in the short-term than QLGN.

Price Growth

MRNS (@Biotechnology) experienced а +1.09% price change this week, while QLGN (@Biotechnology) price change was -7.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

MRNS is expected to report earnings on May 08, 2025.

QLGN is expected to report earnings on Mar 01, 2023.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNS($29.8M) has a higher market cap than QLGN($2.98M). MRNS YTD gains are higher at: 0.729 vs. QLGN (-3.800). QLGN has higher annual earnings (EBITDA): -6.73M vs. MRNS (-122.86M). MRNS has more cash in the bank: 42.2M vs. QLGN (388K). QLGN has less debt than MRNS: QLGN (1.43M) vs MRNS (56M). MRNS has higher revenues than QLGN: MRNS (31.5M) vs QLGN (0).
MRNSQLGNMRNS / QLGN
Capitalization29.8M2.98M999%
EBITDA-122.86M-6.73M1,825%
Gain YTD0.729-3.800-19%
P/E RatioN/A0.00-
Revenue31.5M0-
Total Cash42.2M388K10,876%
Total Debt56M1.43M3,905%
FUNDAMENTALS RATINGS
MRNS vs QLGN: Fundamental Ratings
MRNS
QLGN
OUTLOOK RATING
1..100
2567
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4565
P/E GROWTH RATING
1..100
10042
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (30) in the null industry is in the same range as MRNS (50) in the Pharmaceuticals Other industry. This means that QLGN’s stock grew similarly to MRNS’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that QLGN’s stock grew similarly to MRNS’s over the last 12 months.

QLGN's SMR Rating (100) in the null industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that QLGN’s stock grew similarly to MRNS’s over the last 12 months.

MRNS's Price Growth Rating (45) in the Pharmaceuticals Other industry is in the same range as QLGN (65) in the null industry. This means that MRNS’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's P/E Growth Rating (42) in the null industry is somewhat better than the same rating for MRNS (100) in the Pharmaceuticals Other industry. This means that QLGN’s stock grew somewhat faster than MRNS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRNSQLGN
RSI
ODDS (%)
Bearish Trend 7 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
90%
Momentum
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
69%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend about 1 month ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
77%
N/A
View a ticker or compare two or three
Ad is loading...
MRNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EIG49.351.25
+2.60%
Employers Holdings
FUL63.730.51
+0.81%
HB Fuller Company
FCUV0.58-0.01
-1.92%
Focus Universal
SGHT3.15-0.09
-2.78%
Sight Sciences
BIIB143.06-7.12
-4.74%
Biogen

MRNS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNS has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNS
1D Price
Change %
MRNS100%
-0.39%
AXON - MRNS
40%
Loosely correlated
+1.96%
NTLA - MRNS
37%
Loosely correlated
-3.13%
FOLD - MRNS
36%
Loosely correlated
-0.22%
AMRN - MRNS
35%
Loosely correlated
+0.51%
SAGE - MRNS
33%
Poorly correlated
-0.80%
More

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with VERU. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
-1.22%
VERU - QLGN
34%
Loosely correlated
-2.45%
PHIO - QLGN
32%
Poorly correlated
-45.76%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MRNS - QLGN
28%
Poorly correlated
-0.39%
MNOV - QLGN
28%
Poorly correlated
-4.02%
More